Merck Secures AI Deal with Mayo Clinic to Accelerate IBD and MS Therapies
Merck has entered a first-of-its-kind strategic collaboration with the world’s top-ranked Mayo Clinic to utilize its extensive multimodal clinical and laboratory data for AI-driven drug discovery. The partnership will initially target inflammatory bowel disease, atopic dermatitis and multiple sclerosis to accelerate tailored therapy development.
1. Strategic Collaboration Details
Merck has formed a strategic partnership with Mayo Clinic to integrate advanced analytics and artificial intelligence into drug discovery, tapping into the hospital system’s clinical insights and laboratory results to validate predictive models and streamline target identification.
2. Data Integration and AI Validation
Under the agreement, extensive multimodal data—including imaging, genomic profiles and patient records—will be used to refine algorithms, support biomarker discovery and enhance preclinical development processes across multiple therapeutic areas.
3. Targeted Therapeutic Development
The collaboration will initially focus on inflammatory bowel disease, atopic dermatitis and multiple sclerosis, aiming to accelerate the discovery and optimization of tailored therapies and improve trial candidate selection in high-need disease areas.